82261-42-5

Basic information

• Product Name: 4-(3-PYRIDYL)ANILINE
• Synonyms: 4-(3-PYRIDYL)ANILINE;4-PYRIDIN-3-YL-PHENYLAMINE;4-PYRIDIN-3-YL-PHENYLAMINE DIHYDROCHLORIDE;4-PYRIDIN-3-YLANILINE;2-Pyridyl-4-aniline;3-(4-Aminophenyl)pyridine;4-(3-Pyridinyl)aniline;4-(3-Pyridinyl)benzenamine
• CAS NO: 82261-42-5
• Molecular Formula: C₁₁H₁₀N₂
• Molecular Weight: 170.21
• EINECS: 1533716-785-6
• Product Categories: pharmacetical
• Mol File: 82261-42-5.mol

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 333℃
• Flash Point: 182℃
• Appearance: /
• Density: 1.133
• Vapor Pressure: 0.00014mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-PYRIDYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-PYRIDYL)ANILINE(82261-42-5)
• EPA Substance Registry System: 4-(3-PYRIDYL)ANILINE(82261-42-5)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39-22
• Hazardous Substances Data: 82261-42-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Pyridyl)aniline is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs with different therapeutic properties.
Used in Agrochemical Industry:
4-(3-Pyridyl)aniline is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, to enhance crop protection and yield.
Used in Dye Industry:
4-(3-Pyridyl)aniline is used as a key intermediate in the synthesis of dyes, providing a wide range of color options for various applications, including textiles, plastics, and printing inks.
Used in Organic Synthesis:
4-(3-Pyridyl)aniline is used as a versatile intermediate in organic synthesis, enabling the creation of a variety of compounds with diverse properties for use in different industries.
Used in Environmental Research:
4-(3-Pyridyl)aniline is studied for its potential toxic effects on human health and the environment, aiding in the development of strategies to mitigate its impact as an environmental contaminant.

InChI:InChI=1/C11H10N2/c12-11-5-3-9(4-6-11)10-2-1-7-13-8-10/h1-8H,12H2

Upstream product

• 626-55-1 3-Bromopyridine 
• 33976-43-1 para-aminophenyltrimethoxysilane 
• 220565-63-9 pyridin-3-ylzinc(II) bromide 
• 106-40-1 4-bromo-aniline 
• 540-37-4 p-aminoiodobenzene 
• 626-60-8 3-Chloropyridine 
• 106-47-8 4-chloro-aniline 
• 1692-25-7 3-pyridylboronic acid 
• 586-78-7 para-nitrophenyl bromide 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 59020-10-9 3-(tributylstannyl)pyridine 
• 636-98-6 p-nitrobenzene iodide 
• 5957-97-1 4-(3'-pyridinyl)-1-chlorobenzene 
• 110-86-1 pyridine 

Downstream Products

• 1044209-37-1 C₂₁H₂₃N₃O₂ 
• 1438419-47-6 (R)-5-(1-amino-1-oxobutan-2-ylamino)-3-(4-(pyridin-3-yl)phenylamino)pyrazine-2-carboxamide 

Relevant articles and documents

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)

Starting from the MLPCN probe compound ML300, a structure-based optimization campaign was initiated against the recent severe acute respiratory syndrome coronavirus (SARS-CoV-2) main protease (3CLpro). X-ray structures of SARS-CoV-1 and SARS-CoV-2 3CLpro enzymes in complex with multiple ML300-based inhibitors, including the original probe ML300, were obtained and proved instrumental in guiding chemistry toward probe compound 41 (CCF0058981). The disclosed inhibitors utilize a noncovalent mode of action and complex in a noncanonical binding mode not observed by peptidic 3CLpro inhibitors. In vitro DMPK profiling highlights key areas where further optimization in the series is required to obtain useful in vivo probes. Antiviral activity was established using a SARS-CoV-2-infected Vero E6 cell viability assay and a plaque formation assay. Compound 41 demonstrates nanomolar activity in these respective assays, comparable in potency to remdesivir. These findings have implications for antiviral development to combat current and future SARS-like zoonotic coronavirus outbreaks.

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

Asymmetric pyrene derivatives comprising amine group including pyridinyl group and organic light-emitting diode including the same

The present invention relates to pyrene derivatives represented by the following chemical formula A or the following chemical formula B, and an organic light-emitting diode including the same, wherein substituents Py, Ar1 to Ar3, Z and m are the same as d

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

S-triazine compounds as well as preparation method and application thereof

The invention discloses s-triazine compounds and pharmaceutically acceptable salts thereof; experiments prove that the compounds can be used for treating or preventing diseases related to protein kinase activity, such as leukemia and lymphoma, by inhibiti

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

Synthesis method of S-3-(4-aminophenyl) piperidine

The invention relates to a synthesis method of S-3-(4-aminophenyl) piperidine. The synthetic method of the S-3-(4-aminophenyl) piperidine includes the following steps: taking 3-pyridineboronic acid (I) as a raw material, and preforming Suzuki coupling wit

Triazole naphthoquinone connected aromatic (heterocyclic) ring derivative

The invention belongs to the field of chemical medicine, particularly relates to a micromolecule capable of resisting malignant tumor, acute leukemia and arthritis, multiple sclerosis and immunological rejection and a preparation and application of the mi

One-Pot Palladium-Catalyzed Cross-Coupling Treble of Borylation, the Suzuki Reaction and Amination

A methodology for a sequential palladium-catalyzed cross-coupling procedure consisting of borylation, the Suzuki reaction and amination has been developed for the assembly of molecules with multi-aryl backbones. The linchpin of this development is the meta-terarylphosphine ligand, Cy*Phine, which has been employed as an air- and moisture-stable precatalyst, Pd(Cy*Phine)2Cl2, to improve the efficiency of one-pot borylation–Suzuki reactions. Additionally, the reactivity of the Pd-Cy*Phine system could be tuned to furnish a one-pot, borylation–Suzuki reaction–amination (BSA) cross-coupling treble. The methodology successfully integrated complementary conditions for three distinctly different and modular reactions. Average yields of 74–94% could be achieved for each segment that cumulatively afforded 50–84% yield over the entire three-step sequence in a single pot. (Figure presented.).

Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives

A new series of theophylline analogues containing 1,2,3-triazoles with different amide groups (22-41) has been designed and synthesized, and their biological activities have been evaluated as potential anticancer agents. The anticancer activities of the synthesized compounds were studied in four cancer cell lines viz. lung (A549), colon (HT-29), breast (MCF-7) and melanoma (A375). Furthermore, these compounds were screened for computational ADME and Lipinski's analysis followed by molecular docking and binding energy calculations against the various therapeutic targets involved in cell proliferation. The in vitro results demonstrate that compounds 22, 27, 36 and 40 have pivotal anticancer activity. Among these, compounds 22 and 27 have significant cytotoxic activity in all three cell lines; the in silico docking studies also reveal that compounds 22, 27 and 36 have good dock scores, binding affinities and binding energies towards human epidermal growth factor receptor 2. This is the first report to demonstrate theophylline hybrids containing 1,2,3-triazoles as potential anticancer agents.